These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 11020875)

  • 1. Tauroursodeoxycholic acid administration as adjuvant therapy in cirrhotic patients on transplantation waiting lists.
    Caglieris S; Giannini E; Dardano G; Mondello L; Valente U; Testa R
    Hepatogastroenterology; 2000; 47(34):1045-7. PubMed ID: 11020875
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-year pilot study on tauroursodeoxycholic acid as an adjuvant treatment after liver transplantation.
    Angelico M; Tisone G; Baiocchi L; Palmieri G; Pisani F; Negrini S; Anselmo A; Vennarecci G; Casciani CU
    Ital J Gastroenterol Hepatol; 1999; 31(6):462-8. PubMed ID: 10575563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of Model for End-Stage Liver Disease (MELD) score in a liver transplantation waiting list.
    Ferraz-Neto BH; Hidalgo R; Thomé T; Melo VA; Lobue A; Zurstrassen MP; Moraes JM; Meira-Filho SP; Rezende MB; Fonseca LE; Pandullo FL; Soeiro FS; Afonso RC
    Transplant Proc; 2007 Oct; 39(8):2511-3. PubMed ID: 17954160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary osteoporosis in liver transplant recipients: a longitudinal study in patients with and without cholestatic liver disease.
    Bjøro K; Brandsaeter B; Wiencke K; Bjøro T; Godang K; Bollerslev J; Schrumpf E
    Scand J Gastroenterol; 2003 Mar; 38(3):320-7. PubMed ID: 12737449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aminopyrine breath test compared to the MELD and Child-Pugh scores for predicting mortality among cirrhotic patients awaiting liver transplantation.
    Degré D; Bourgeois N; Boon N; Le Moine O; Louis H; Donckier V; El Nakadi I; Closset J; Lingier P; Vereerstraeten P; Gelin M; Adler M
    Transpl Int; 2004 Jan; 17(1):31-8. PubMed ID: 14745489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The model for end-stage liver disease score is the best prognostic factor in human immunodeficiency virus 1-infected patients with end-stage liver disease: a prospective cohort study.
    Murillas J; Rimola A; Laguno M; de Lazzari E; Rascón J; Agüero F; Blanco JL; Moitinho E; Moreno A; Miró JM;
    Liver Transpl; 2009 Sep; 15(9):1133-41. PubMed ID: 19718643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
    Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
    Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular adsorbents recirculating system treatment in acute-on-chronic hepatitis patients on the transplant waiting list improves model for end-stage liver disease scores.
    Novelli G; Rossi M; Pugliese F; Poli I; Ruberto E; Martelli S; Nudo F; Morabito V; Mennini G; Berloco PB
    Transplant Proc; 2007; 39(6):1864-7. PubMed ID: 17692635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study.
    Crosignani A; Budillon G; Cimino L; Del Vecchio Blanco C; Loguercio C; Ideo G; Raimondo G; Stabilini R; Podda M
    Hepatogastroenterology; 1998; 45(23):1624-9. PubMed ID: 9840118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model for End-Stage Liver Disease (MELD) score system to evaluate patients with viral hepatitis on the waiting list: better than the Child-Turcotte-Pugh (CTP) system?
    Cuomo O; Perrella A; Arenga G
    Transplant Proc; 2008; 40(6):1906-9. PubMed ID: 18675085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morbidity and mortality during renal replacement therapy: dialysis versus transplantation.
    Straathof-Galema L; van Saase JL; Verburgh CA; de Fijter JW; Schut NH; van Dorp WT
    Clin Nephrol; 2001 Mar; 55(3):227-32. PubMed ID: 11316243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Change in model for end-stage liver disease score on the transplant waiting list predicts survival in patients undergoing liver transplantation.
    Foxton MR; Kendrick S; Sizer E; Muiesan P; Rela M; Wendon J; Heaton ND; O'Grady JG; Heneghan MA
    Transpl Int; 2006 Dec; 19(12):988-94. PubMed ID: 17081228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
    Marsman D
    Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C virus-related cirrhosis as a significant mortality factor in intention-to-treat analysis in liver transplantation.
    Gringeri E; Vitale A; Brolese A; Zanus G; Boccagni P; Neri D; Valmasoni M; D'Amico F; Ciarleglio FA; Carraro A; Pauletto A; Violi P; Bassi D; D'Amico F; D'Amico DF; Cillo U
    Transplant Proc; 2007; 39(6):1901-3. PubMed ID: 17692648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program
    Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ursodeoxycholic acid treatment in isolated chronic graft-vs.-host disease of the liver.
    Arat M; Idilman R; Soydan EA; Soykan I; Erden E; Karayalçin S; Akan H
    Clin Transplant; 2005 Dec; 19(6):798-803. PubMed ID: 16313328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Algorithm for prioritization of patients on the waiting list for liver transplantation.
    Gambato M; Senzolo M; Canova D; Germani G; Tomat S; Masier A; Russo FP; Perissinotto E; Zanus G; Cillo U; Burra P
    Transplant Proc; 2007; 39(6):1855-6. PubMed ID: 17692632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Model for end-stage liver disease: did the new liver allocation policy affect waiting list mortality?
    Austin MT; Poulose BK; Ray WA; Arbogast PG; Feurer ID; Pinson CW
    Arch Surg; 2007 Nov; 142(11):1079-85. PubMed ID: 18025337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilirubin appears to be the only independent variable affecting mortality on liver transplant waiting list if waiting time exceeds 1 year.
    Lee YM; Wai CT; Da Costa M; Lee KH; Sutedja D; Tan KC; Isaac J; Lim SG
    Transplant Proc; 2005 Dec; 37(10):4365-6. PubMed ID: 16387121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.